Reading Time:

8 minutes

Diabetic Cardiomyopathy – An Overview

Diabetic Cardiomyopathy is a concept that was first introduced about 30 years ago. While almost every healthcare professional is aware of the increased morbidity and mortality rates of cardiac disease in diabetics, correlating cardiomyopathy due to hyperglycemia without considering current blood pressure and coronary artery disease has always caused interest in the medical community. However, many fields of study indicate that hyperglycemia is a major culprit of cardiac dysfunction as it relates to diabetes since chronically high levels of blood glucose cause physical damage to the microvasculature and coronary arteries. 

“The current typical definition of diabetic cardiomyopathy comprises structural and functional abnormalities of the myocardium in diabetic patients without coronary artery disease or hypertension. Obviously, however, this type of cardiomyopathy should be present also in diabetics with coronary artery disease and/or hypertension, though it is difficult to separately assess the contribution of diabetic cardiomyopathy to overall ventricular dysfunction in such cases.”1 

Due to the parallels in the rise of diabetes mellitus along with cardiomyopathy, further research must arise to clearly understand diabetic induced cardiomyopathy and its mortality rates.

“The cardiovascular disease-related mortality with diabetes mellitus is ~65%. Therefore, diabetes mellitus is regarded as a risk equivalent to coronary heart disease. Diabetic heart disease is a growing and important public health risk. It affects the heart in three ways: cardiac autonomic neuropathy (CAN), coronary artery disease (CAD) due to accelerated atherosclerosis, and diabetic cardiomyopathy (DCM). DCM is characterized by lipid accumulation in cardiomyocytes, fetal gene reactivation, and left ventricular (LV) hypertrophy, which together result in contractile dysfunction.”2

Cardiac Responses to Diabetes

Scientists have recorded various cardiac deformities and abnormal cardiac functions in animals with diabetes. In the 70s and 80s, a team of researchers induced diabetes in canines using a drug called Alloxan. The researchers examined the hemodynamics, biochemical and histological findings of cardiac muscles of these animals. They found a decrease in the quantity of blood the ventricles expel per contraction even though ventricular and diastolic pressure never faltered. The diabetes-induced dogs also experimented hardening of cardiac chambers versus the healthy control dogs, despite the use of insulin.

In rats, extended isovolumetric contractions and diastole occurred along with ventricular hypertrophy and the aforementioned chamber hardening. They observed the following biochemical alterations:

  • ATPase and Isoenzymes
  • Impairment of Calcium Ion Transport
  • Alterations in Receptor functionality
  • Alterations in the metabolism of lipids, carbs and adenine nucleotide translocator

The findings in animal research reinforce the effect of cardiomyopathy and diabetes.

“The pathophysiological mechanisms of DCM (diabetic cardiomyopathy) have not yet been sufficiently elucidated. The occurrence of DCM is multifactorial, and there are various proposed mechanisms including insulin resistance, microvascular impairment, subcellular component abnormalities, metabolic disturbances, cardiac autonomic dysfunction, alterations in the renin-angiotensin-aldosterone system (RAAS), and maladaptive immune responses.”3


Diabetic Cardiomyopathy
Pathophysiological mechanisms of diabetic cardiomyopathy.(4)

Coronary artery disease develops at a young age. Small vessel disease is partly responsible for diabetic cardiomyopathy, but ventricular hypertrophy and its contributions to it are underestimated. Because of the strong association between hypertension and diabetes, it follows that ventricular hypertrophy is a result of hypertension.

“There are different structural and functional modifications in the myocardial tissue after diabetes. These events emerge from metabolic alterations induced by hyperglycemia, insulin resistance, and hyperlipidemia. The lack of insulin sensitivity and glucose assimilation in the heart is evident by the reduction in the number of glucose transporters Glut1, and mainly, Glut4. In this line, impaired fasting glucose and left ventricular diastolic dysfunction have been correlated in middle-aged adults. As a compensatory mechanism, fatty acid transporters are increased, and most ATP generation relies on fatty acid degradation. However, fatty acid may saturate ß-oxidation and accumulate in the cytosol, leading to lipotoxic effects by the generation of ceramides, diacylglycerol and reactive species of oxygen (ROS). In this sense, hyperglycemia elicits also ROS and advanced glycation product (AGE) formation, which leads to cardiac glucotoxicity. Both, the lack of fuel and lipo/glucotoxicity are promoters of calcium imbalance, mitochondrial/endoplasmic reticulum failure and apoptosis, triggering cardiac low-grade chronic inflammation, fibrosis, and contractile dysfunction. Among others, the renin-angiotensin-aldosterone (RAA) and TGFß systems, together with specific cytokine/chemokine production, are remarkably enhanced.”5 

Although, diabetic women appear to have a tendency towards larger ventricular sizes than diabetic men. As such, specialists propose that increased ventricular mass occurs in diabetic patients independently from high blood pressure. Common deformities affecting cardiac integrity in diabetic patients include:

  • Microvascular narrowing
  • Interstitial Fibrosis
  • Edema

Hypertension aggravates any cardiac problem and is a warning sign that predicts congestive heart failure.

“Currently, the best approach to the diagnosis of diabetic cardiomyopathy is the detection of functional and structural changes in the LV (left ventricular) and exclusion of other heart diseases being responsible for the changes in a diabetic patient.

Diagnostic clues of diabetic cardiomyopathy

Structural changes

  • LV (left ventricular) hypertrophy assessed by 2D echocardiography or CMR (cardiac magnetic resonance imaging.
  • Increased integrated backscatter in the LV (left ventricular) (septal and posterior wall)
  • Late Gd-enhancement of the myocardium in CMR (cardiac magnetic resonance imaging)

Functional changes

  • LV (left ventricular) diastolic dysfunction assessed by pulsed Doppler echocardiography and TDI (tissue Doppler imaging)
  • LV (left ventricular) systolic dysfunction demonstrated by TDI (tissue Doppler imaging) /SRI (strain/strain rate imaging.
  • Limited systolic and/or diastolic functional reserve assessed by exercise TDI (tissue Doppler imaging)

Metabolic changes

  • Reduced cardiac PCr/ATP detected by 31P-MRS (magnetic resonance spectroscopy)
  • Elevated myocardial triglyceride content detected by 1H-MRS (magnetic resonance spectroscopy).”6

Diagnosis of Heart Failure in Diabetic Patients

“Diabetic patients arriving at emergency departments with symptoms of HF (heart failure) are examined by non-invasive tests such as chest X-ray, to assess fluid accumulation in the lungs, electrocardiography, to identify ventricular overload, and conventional cardiac ultrasound, to assess structural and functional abnormalities of the myocardium. Additionally, natriuretic peptides plasma levels may also be of help in the diagnosis of heart failure. Other biomarkers not used in the clinical practice in this setting, could provide also additional information. These biomarkers can be released after a wide variety of cardiac and/or skeletal muscle injuries such as inflammation (i.e., C-reactive protein), hypertrophy/stiffness and necrosis (i.e., troponins) in relation to different diseases such as myocardial infarction, arrhythmia, myocarditis, hypertension, or any secondary cardiac injury (i.e., chemotherapy, renal kidney disease). Thus, recent human and mainly pre-clinical data suggest new techniques for the detection of premature DCM (diabetic cardiomyopathy) based on imaging and biomarkers analysis.”7 


“Nowadays, this non-invasive approach is the gold standard diagnostic tool to identify structural cardiac disorders. It provides a reliable identification of the structural abnormalities seen in the early stages of DCM (diabetic cardiomyopathy), such as impaired diastolic filling and left ventricle hypertrophy. It can also be helpful for the assessment of the progression of the disease and evaluation of treatments. Echocardiography has been widely studied in rodent models even without using anesthesia, and thus, eluding the cardiodepressant effect. Several modalities can be used.”8

Risk factors for Diabetic Cardiomyopathy

Thanks to experimental findings and data, diabetes is now accepted as a risk factor for cardiac disease. Heart failure is doubly prevalent in men with diabetes than their healthy male counterparts. 

In contrast, diabetic women have a 5 times greater tendency to suffer heart failure than non-diabetic women. The hazard for congestive heart failure remains despite adjusting the data for age, weight and an underlying presence of hypertension, hypercholesterolemia, and coronary heart disease. 

Diabetic Cardiomyopathy and Quality of Life

“Heart failure leads to poor quality of life in affected individuals and complicates the treatment of diabetes mellitus by altering the pharmacokinetics of anti-diabetic medications. Thus, both the prompt diagnosis and early management of these patients are of utmost importance. However, DCM (Diabetic Cardiomyopathy) is poorly understood by most physicians, even cardiologists, and diabetologists.”9 

While diabetes and hypertension are independently deadly in and of themselves, a synergy or cooperation between the two may cause heart failure. The medical community believes that treating high blood pressure with ACE (Angiotensin Converting Enzyme Inhibitor) in diabetic patients will impede the progression of Diabetic Cardiomyopathy. However, the standardization of treatment with ACE is still pending as more data appears and conclusive results emerge.

Therapeutic Approaches

“There is a considerable body of epidemiological evidence that implicates obesity, linked to increased intake of refined carbohydrates and decreased exercise, in the increasing prevalence of diabetes and related heart disease throughout the world. Lifestyle changes such as aerobic exercise, weight control and smoking cessation are efficacious therapeutic approaches in the prevention of diabetic cardiomyopathy. Sustained glycemic control reduces the prevalence of diabetic cardiomyopathy and reduces cardiovascular disease (CVD). For example, normalization of glycemia with insulin therapy reduced cardiomyocyte hypertrophy, collagen content and diastolic dysfunction and limited progression of diabetic cardiomyopathy in type 1 diabetic rodent models. There is emerging evidence that some glycemic therapies may have specific benefits. In a retrospective cohort study of 10,920 patients, metformin use was associated with a low risk of mortality in diabetic individuals with heart failure. Sodium–glucose cotransporter (SGLT) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists have beneficial effects on CVD (cardiovascular disease) outcomes in type 2 diabetic patients.”10 


“The cardinal features of diabetic cardiomyopathy include cardiac stiffness, myocardial fibrosis and hypertrophy with cardiac diastolic dysfunction and subsequent progression to both systolic dysfunction and clinical heart failure. Importantly, hyperglycemia and systemic and cardiac insulin resistance are independently associated with the development and progression of cardiac dysfunction and heart failure in diabetes. From a mechanistic point of view, mitochondrial dysfunction, oxidative stress, increased formation and deposition of AGEs, impaired mitochondrial Ca2+ handling and function, inflammation, activation of RAAS (renin-angiotensin-aldosterone system) and SNS (central nervous system), cardiac autonomic neuropathy, endoplasmic reticulum stress, microvascular dysfunction, and cardiac metabolic disorders are involved in the pathophysiological process.”11

A Lack of Diagnosis Criteria Impedes a Formal Definition fo Diabetic Cardiomyopathy 

“Although diabetic cardiomyopathy appears to have an extensive preclinical course and the pathophysiological changes appear to be induced by the metabolic alterations in diabetes mellitus, a formal definition for diabetic cardiomyopathy as a distinct clinical entity remains vague due to a lack of accepted diagnostic criteria and information on subclinical CVD (cardiovascular disease) in the early stages of diabetes. Currently, there is not a specific histological property, biochemical marker, or clinical manifestation for the definitive diagnosis of diabetic cardiomyopathy. Also, there are no prospective clinical trials to support that hyperglycemia or hyperinsulinemia independently increase the risk for the development of diabetic cardiomyopathy in the absence of other risk factors such as obesity, coronary heart disease, and hypertension. Recent scientific evidence for the potential use of exosome and circulating miRNAs as biomarkers for the detection of diabetic cardiomyopathy highlights emerging methods for the diagnosis and prevention of diabetes and cardiomyopathy.”12 

Increases in obesity and diabetes mellitus produce a rise in morbidity and mortality rates. Diabetic patients have a tendency for negative outcomes in clinical procedures associated with heart failure. Diabetic Cardiomyopathy appears as a myocardial dysfunction in patients without evident clinical coronary artery disease and other regular cardiovascular risk factors. The medical community requires additional studies to define the mechanisms that trigger and induce the advancement of diabetic cardiomyopathy, and the development of approaches to diminish the chances of heart failure in diabetic patients.


(1, 6) Diabetic cardiomyopathy: pathophysiology and clinical features. Miki, T., Yuda, S., Kouzu, H., & Miura, T. Heart Failure Reviews. 2013. 

(2, 3, 4, 9) Diabetic cardiomyopathy: where we are and where we are going. Lee, W.S. & Kim, J. Korean Journal of Internal Medicine. 2017. 

 (5, 7, 8) Diagnostic approaches for diabetic cardiomyopathy. Lorenzo-Almorós, A., Tuñón, J., Orejas, M. Cortés, M., Egido, J. & and Lorenz, Ó. Cardiovascular Diabetology. 2017. 

(10, 11, 12) Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Jia, G., Hill, M.A. & Sowers, J.R. Circulation Research. 2019. 

María Laura Márquez
13 October, 2018

Written by

María Laura Márquez, general doctor graduated from The University of Oriente in 2018, Venezuela. My interests in the world of medicine and science, are focused on surgery and its breakthroughs. Nowadays I practice my more:

2 thoughts on “Diabetic Cardiomyopathy – An Overview

  1. daptomycin, sold under the brand name cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by gram-positive organisms. it is a naturally occurring compound found in the soil saprotroph streptomyces roseosporus. its distinct mechanism of action makes it useful in treating infections caused by multiple drug-resistant bacteria.

    daptomycin was removed from the world health organization’s list of essential medicines in 2019. the world health organization classifies daptomycin as critically important for human medicine.

    medical uses
    daptomycin is indicated for use in adults in the united states for skin and skin structure infections caused by gram-positive infections, s. aureus bacteraemia, and right-sided s. aureus endocarditis. it binds avidly to pulmonary surfactant, so cannot be used in the treatment of pneumonia. there seems to be a difference in working daptomycin on hematogenous pneumonia.

    adverse effects
    common adverse drug reactions associated with daptomycin therapy include:

    cardiovascular: low blood pressure, high blood pressure, swelling
    central nervous system: insomnia
    dermatological: rash
    gastrointestinal: diarrhea, abdominal pain
    hematological: eosinophilia
    respiratory: dyspnea
    other: injection site reactions, fever, hypersensitivity
    less common, but serious adverse events reported in the literature include

    hepatotoxicity: elevated transaminases
    nephrotoxicity: acute kidney injury from rhabdomyolysis
    also, myopathy and rhabdomyolysis have been reported in patients simultaneously taking statins, but whether this is due entirely to the statin or whether daptomycin potentiates this effect is unknown. due to the limited data available, the manufacturer recommends that statins be temporarily discontinued while the patient is receiving daptomycin therapy. creatine kinase levels are usually checked regularly while individuals undergo daptomycin therapy.

    in july 2010, the fda issued a warning that daptomycin could cause life-threatening eosinophilic pneumonia. the fda said it had identified seven confirmed cases of eosinophilic pneumonia between 2004 and 2010 and an additional 36 possible cases. the seven confirmed victims were all older than 60 and symptoms appeared within two weeks of initiation of therapy.

Leave a Reply to tcsgroupy Cancel reply

If you would also like a response sent to your email please add it in the email box below.